Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run" is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Fierce Pharma, WSJ, Investor's Business Daily and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 36d ago.
Quick answers
Why is "Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run" trending?
Because 7 independent news sources published 7 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- Argenx walks away from Vyvgart Sjögren's disease trial after futility flag Fierce Pharma · 39d ago
- Argenx Shares Plunge After Autoimmune-Disease Trial Halt WSJ · 39d ago
- Former Highflying Biotech Hits The Skids On A Surprise Failure Investor's Business Daily · 39d ago
- Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters · 39d ago
- Why Is ARGX Stock Plunging Today? Yahoo Finance · 39d ago
- Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease STAT · 39d ago
- Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run Fierce Biotech · 39d ago
Topics
Related trends
Argenx to acquire Unnatural Products in deal worth up to $1.15B
Argenx agrees to acquire Unnatural Products for up to $1.15 billion, betting on AI-guided macrocycle technology to expand oral peptide drug development.
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Argenx to Buy Forte Biosciences for $2.2 Billion
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.